GPP
RNAM

Great Point Partners’s Avidity Biosciences RNAM Stock Holding History

Great Point Partners’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500,000
Closed -$7.26M – 46
2022
Q2 		$7.26M Hold
500,000
– – 1.74% 22
2022
Q1 		$9.23M Hold
500,000
– – 2.23% 19
2021
Q4 		$11.9M Buy
+500,000
New +$11.9M 2.64% 17

Other funds holding RNAM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Great Point Partners's RNAM Position: Q3 2022 in Review

Great Point Partners sold out of Avidity Biosciences (RNAM) in Q3 2022, closing a stake of 500,000 shares — an estimated $7.26M sold.

Great Point Partners first reported a position in RNAM in Q4 2021 and held it in 3 quarters. The position peaked at $11.9M in Q4 2021. 127 funds tracked by Wall St. Rank hold RNAM as of Q3 2022.

  • Great Point Partners reported no remaining Avidity Biosciences position as of Q3 2022 after selling out during the quarter.
  • Great Point Partners sold 500,000 Avidity Biosciences shares in Q3 2022, an estimated $7.26M.
  • Great Point Partners first reported a position in Avidity Biosciences in Q4 2021 and held it in 3 quarters.
  • Great Point Partners's Avidity Biosciences position peaked at $11.9M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2022.

Based on Great Point Partners's 13F filing for Q3 2022, filed 14 Nov 2022.